Innovative Delivery Technology for Gene and Cell Therapy

19 Jan 2022
11:00
New & Enabling Technologies Track
SPONSORED BY
Avectas

11:00am Chair Introduction

Vincent Ling, Head of Search and Evaluation for Drug Delivery Technologies, Takeda

 

11:05am Presentation: TBA

Pierre Boulas, Head of Medical Devices and Packaging Development, Biogen

 

11:20am Presentation: How Do We Produce A Healthy and Highly-Functioning Gene-Edited Immune Cell?

  • Solupore is a non-viral transfection process that enables complex, multi-step editing for next-generation cell therapy products
  • Primary cells edited using Solupore® retain high levels of stem-cell memory cells with minimal apoptosis
  • Following editing with Solupore®, cells demonstrate enhanced functional response and cytotoxicity compared with existing transfection technologies

Justin McCue, Chief Technical Officer, Avectas

 

11:35am Presentation: TBA

Senior Representative, Spirovant

 

11:50am Presentation: TBC

Speaker TBC

 

12:05pm Closing Panel with Q&A

With all session participants

Speakers

Justin McCue
Chief Technical Officer
Avectas
Pierre Boulas
Head of Medical Devices and Packaging Development
Biogen
Vincent Ling
Senior Director
Takeda